Drugs / NA-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02056574 | Nov 2015 → Nov 2019 | brain aneurysm, subarachnoid hemorrhage | NoNO Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00728182 | Aug 2008 → Apr 2011 | stroke disorder | NoNO Inc. | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NA-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00728182 ↗ |
| Known as | Tat-NR2B9c | “Neuroprotection with NA-1 (Tat-NR2B9c), an inhibitor of postsynaptic density-95 protein, has been shown in a primate model of stroke.” PMID 23051991 ↗ Oct 2012 |
| Action | Inhibit | “an inhibitor of postsynaptic density-95 protein” PMID 23051991 ↗ Oct 2012 |
| Modality | Peptide | “20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.” NCT00728182 ↗ |
| Route | Intravenous | “intravenous infusion” NCT00728182 ↗ |